236 related articles for article (PubMed ID: 14559849)
1. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP
Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849
[TBL] [Abstract][Full Text] [Related]
2. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
3. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
4. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
[TBL] [Abstract][Full Text] [Related]
6. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network.
Stephan C; Meyer HA; Cammann H; Nakamura T; Diamandis EP; Jung K
Biol Chem; 2006 Jun; 387(6):801-5. PubMed ID: 16800743
[TBL] [Abstract][Full Text] [Related]
7. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
Stephan C; Xu C; Brown DA; Breit SN; Michael A; Nakamura T; Diamandis EP; Meyer H; Cammann H; Jung K
Prostate; 2006 May; 66(6):651-9. PubMed ID: 16388506
[TBL] [Abstract][Full Text] [Related]
8. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
9. mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy.
Scorilas A; Gregorakis AK
Biol Chem; 2006 Jun; 387(6):789-93. PubMed ID: 16800741
[TBL] [Abstract][Full Text] [Related]
10. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
11. [The percentage of free prostate specific antigen used in detecting prostate cancer].
Yang L; Fang Z; Song J; Deng S
Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
[TBL] [Abstract][Full Text] [Related]
12. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
14. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
15. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
16. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
[TBL] [Abstract][Full Text] [Related]
17. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
[TBL] [Abstract][Full Text] [Related]
18. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
19. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
20. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
